NYSE: NVS
Positive Data on Novartis' Jakavi - Analyst Blog
Positive Data on Novartis' Jakavi - Analyst BlogThis Blockbuster Biologic May Face a Steep Cliff
Neulasta generated sales north of $4 billion for Amgen in 2012, but generic competition is brewing on two continents.3 Humongous Health-Care Stocks This Week
These stocks skyrocketed this week. But will gravity soon kick in?Encouraging Data on Novartis' Gilenya - Analyst Blog
Encouraging Data on Novartis' Gilenya - Analyst Blog1 Thing You Always Wanted to Know About Drugs (but Were Afraid to Ask)
Two fascinating approaches pharmaceutical companies use to discover new drugs.